Friday 6 November 2026 Export KNSA’s income statement to Excel — free account

Kiniksa Pharmaceuticals International, plc

KNSA Healthcare Drug Manufacturers Specialty & Generic

Kiniksa Pharmaceuticals International, plc’s revenue for fiscal 2025 (year ended December 2025) was $677.6 million, up 60.1% from fiscal 2024.

Revenue: +58.1%
EPS: +142.2%
Free cash flow: +43.5%

Quarter to September 2026, against a year earlier

88.50 7.62 −7.93%

Follow KNSA

Alert me

Market cap: $6.9B
P/E: 62.1×
Fwd P/E: 67.8×
Dividend yield: —
F-score: 8/9
Altman Z: 10.35
Beneish M: −3.16
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Kiniksa Pharmaceuticals International, plc (KNSA) P/B ratio

Alert me on P/B ratio

As of 5 November 2026, Kiniksa Pharmaceuticals International, plc (KNSA) trades at a P/B ratio of 9.7×. Over the past ten years it has ranged from 0.0× (June 2018) to 10.7× (October 2026); the current reading is higher than 100% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 1.8× and above the Healthcare sector median of 2.3×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/KNSA/pb-ratio" width="100%" height="360" style="border:0" loading="lazy" title="Kiniksa Pharmaceuticals International, plc P/B ratio, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/KNSA/metrics/pb-ratio">Kiniksa Pharmaceuticals International, plc (KNSA) P/B ratio — stockrow.com</a></p>

Period	P/B ratio	Change
FY2025	5.4×	67.35%
FY2024	3.2×	8.93%
FY2023	3.0×	16.97%
FY2022	2.5×	(42.02%)
FY2021	4.4×	—

Period	P/B ratio	Change
Sep 2026	8.2×	8.31%
Jun 2026	7.6×	24.68%
Mar 2026	6.1×	12.80%
Dec 2025	5.4×	(0.49%)
18 more quarters	Free account

Against its own ten years

Low 0.0× High 10.7×

Ten-year median 3.5×

Current reading's percentile 100

Company	P/B ratio
SUPN Indivior Pharmaceuticals Inc. compare	n/m
ELAN Elanco Animal Health Incorporated compare	1.8×
RDY Dr. Reddy's Laboratories Ltd compare	3.0×
ALKS Alkermes plc compare	4.0×
LNTH Lantheus Holdings, Inc. compare	4.9×
KNSA Kiniksa Pharmaceuticals International, plc	9.7×
HIMS Hims & Hers Health, Inc. compare	17.2×
LQDA Liquidia Corporation compare	20.4×
AMRX AMNEAL PHARMACEUTICALS, INC. compare	59.5×
Drug Manufacturers Specialty & Generic industry median	1.8×
Healthcare sector median	2.3×
Market median	1.7×

What P/B ratio is

Price to Book Value tells an investor how much the market pays for a company’s shares relative to the accounting net worth that belongs to common shareholders.

Stock Price ÷ (Common Equity (Total) (latest quarter) ÷ Shares (Basic, Weighted) (latest quarter))

The full definition of P/B ratio →

Kiniksa Pharmaceuticals International, plc (KNSA) P/B ratio

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on KNSA

P/B ratio, daily

Annual newest first

Quarterly newest first

Against its own ten years

P/B ratio against peers

What P/B ratio is

More on KNSA

Stockrow Weekly